Table 3 .
Cox Regression Analysis of Overall Survival with Substratification by Tumor Size
| High Tumor 2D Measurement | Low Tumor 2D Measurement | High Tumor 3D Measurement | Low Tumor 3D Measurement | ||
|---|---|---|---|---|---|
| Hazard Ratio (95% CI), P Value | Hazard Ratio (95% CI), P Value | Hazard Ratio (95% CI), P Value | Hazard Ratio (95% CI), P Value | ||
| Age at Treatment Initiation | 1.020 (0.994-1.047), P = .138 | 1.034 (1.007-1.062), P = .012 | 1.016 (0.986-1.046), P = .298 | 1.026 (1.001-1.052), P = .046 | |
| KPS at First Recurrent Treatment | <70 | Reference | Reference | Reference | Reference |
| ≥70 | 0.678 (0.303-1.516), P = .344 | 0.421 (0.197-0.898), P = .025 | 0.833 (0.404-1.718), P = .620 | 0.246 (0.105-0.577), P = .001 | |
| Treatment Group | CCNU 01-04 | Reference | Reference | Reference | Reference |
| Bev | 0.218 (0.095-0.497), P < .001 | 0.847 (0.379-1.895), P = .687 | 0.507 (0.249-1.032), P = .061 | 0.631 (0.260-1.531), P = .309 | |
| Bev/CCNU | 0.234 (0.104-0.523), P < .001 | 0.606 (0.263-1.398), P = .241 | 0.441 (0.221-0.879), P = .020 | 0.532 (0.214-1.319), P = .173 | |
| CCNU 09-15 | 0.076 (0.020-0.295), P < .001 | 0.350 (0.166-0.740), P = .006 | 0.133 (0.029-0.604), P = .009 | 0.292 (0.123-0.690), P = .005 | |
Abbreviations: 2D, 2-dimensional; 3D, 3-dimensional; Bev, bevacizumab; CCNU, lomustine; CI, confidence interval; KPS, Karnofsky Performance Status; OS, overall survival.